Mena Raouf1, Jeffrey Bettinger2, Erica W Wegrzyn3, Roy O Mathew4, Jeffrey J Fudin3. 1. Department of Pain Management, Kaiser Permanente, Federal Way, Washington, USA. 2. Department of Pain Management, Saratoga Hospital Medical Group, Saratoga, New York, USA. 3. Department of Pain Management, Stratton VA Medical Center, Albany, New York, USA. 4. Department of Nephrology, William Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina, USA.
Abstract
BACKGROUND: Chronic noncancer pain is pervasive throughout the general patient population, transcending all chronic disease states. Patients with end-stage renal disease (ESRD) present a complicated population for which medication management requires careful consideration of the pathogenesis of ESRD and intimate knowledge of pharmacology. The origin of pain must also guide treatment options. As such, the presentation of neuropathic pain in ESRD can present a challenging case. The authors aim to provide a review of available classes of medications and considerations for the treatment of neuropathic pain in ESRD. SUMMARY: In this narrative review, the authors discuss important strategies and considerations for the treatment of neuropathic pain in ESRD, including the pathogenesis of neuropathic pain, physiological changes for consideration in ESRD patients, and disease-specific consideration for medication selection. Pharmacotherapeutic classes discussed include: anticonvulsants, antiarrhythmics, antidepressants, topicals, and opioids. KEY MESSAGE: Pain management in ESRD patients requires careful assessment of drug-specific properties, accumulation, metabolism (presence of active/toxic metabolites), extraction by dialysis, and presence of drug - drug interactions. In the absence of pharmacokinetic data in ESRD patients, therapeutic window and potential risks should be factored in the decision making along with continued monitoring throughout therapy.
BACKGROUND: Chronic noncancer pain is pervasive throughout the general patient population, transcending all chronic disease states. Patients with end-stage renal disease (ESRD) present a complicated population for which medication management requires careful consideration of the pathogenesis of ESRD and intimate knowledge of pharmacology. The origin of pain must also guide treatment options. As such, the presentation of neuropathic pain in ESRD can present a challenging case. The authors aim to provide a review of available classes of medications and considerations for the treatment of neuropathic pain in ESRD. SUMMARY: In this narrative review, the authors discuss important strategies and considerations for the treatment of neuropathic pain in ESRD, including the pathogenesis of neuropathic pain, physiological changes for consideration in ESRD patients, and disease-specific consideration for medication selection. Pharmacotherapeutic classes discussed include: anticonvulsants, antiarrhythmics, antidepressants, topicals, and opioids. KEY MESSAGE: Pain management in ESRD patients requires careful assessment of drug-specific properties, accumulation, metabolism (presence of active/toxic metabolites), extraction by dialysis, and presence of drug - drug interactions. In the absence of pharmacokinetic data in ESRD patients, therapeutic window and potential risks should be factored in the decision making along with continued monitoring throughout therapy.
Authors: Claudia M Campbell; Mark S Kipnes; Bruce C Stouch; Kerrie L Brady; Margaret Kelly; William K Schmidt; Karin L Petersen; Michael C Rowbotham; James N Campbell Journal: Pain Date: 2012-06-08 Impact factor: 6.961
Authors: William C Becker; Michael J Fischer; Daniel G Tobin; Mark B Lockwood; Paul L Kimmel; Laura M Dember; Nwamaka D Eneanya; Manisha Jhamb; Thomas D Nolin Journal: Nat Rev Nephrol Date: 2021-10-07 Impact factor: 28.314
Authors: Mark B Lockwood; Michael J Fischer; Kimberly Silva; Blanca N Contreras; Guillermo Zamora; Amanda Goldstein; Monya Meinel; Christopher Holden; James Lash; Alana Steffens; Ardith Doorenbos Journal: Contemp Clin Trials Commun Date: 2022-09-05